Last reviewed · How we verify
Centre for Infectious Disease Research in Zambia — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
2 Phase 3
0 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PrEP | PrEP | marketed | ||||
| ROTAVAC 5D | ROTAVAC 5D | phase 3 | Vaccine | Infectious Diseases | ||
| ROTAVAC® | ROTAVAC® | phase 3 | Infectious Diseases |
Therapeutic area mix
- Infectious Diseases · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Minhai Biotechnology Co., Ltd · 1 shared drug class
- Bharat Biotech International Limited · 1 shared drug class
- BioNTech · 1 shared drug class
- Boryung Pharmaceutical Co., Ltd · 1 shared drug class
- CanSino Biologics Inc. · 1 shared drug class
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · 1 shared drug class
- China National Biotec Group Company Limited · 1 shared drug class
- Arcturus Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Centre for Infectious Disease Research in Zambia:
- Centre for Infectious Disease Research in Zambia pipeline updates — RSS
- Centre for Infectious Disease Research in Zambia pipeline updates — Atom
- Centre for Infectious Disease Research in Zambia pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Centre for Infectious Disease Research in Zambia — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/centre-for-infectious-disease-research-in-zambia. Accessed 2026-05-17.